Selected research
Industry Research
Glycoprotein 41 Industry Research Report 2026
Market perspective
The global Glycoprotein 41 market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Glycoprotein 41 is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Glycoprotein 41 is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Glycoprotein 41 is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Glycoprotein 41 include Amunix Operating Inc, Frontier Biotechnologies Inc, InnaVirVax SA, Longevity Biotech Inc, Mymetics Corp, Navigen Inc, Osel Inc and Pharis Biotec GmbH, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Glycoprotein 41 market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Glycoprotein 41 Market by Company
Amunix Operating Inc
Frontier Biotechnologies Inc
InnaVirVax SA
Longevity Biotech Inc
Mymetics Corp
Navigen Inc
Osel Inc
Pharis Biotec GmbH
Glycoprotein 41 Segment by Type
DS-007
LBT-5001
LBT-5001
MYMV-101
Others
Glycoprotein 41 Segment by Application
Hospital
Clinic
Others
Glycoprotein 41 Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Glycoprotein 41 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Glycoprotein 41 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Glycoprotein 41.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Glycoprotein 41 manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Glycoprotein 41 by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Glycoprotein 41 in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- DS-007
- LBT-5001
- LBT-5001
- MYMV-101
- Others
Applications
- Hospital
- Clinic
- Others
Companies covered
- Amunix Operating Inc
- Frontier Biotechnologies Inc
- InnaVirVax SA
- Longevity Biotech Inc
- Mymetics Corp
- Navigen Inc
- Osel Inc
- Pharis Biotec GmbH
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Glycoprotein 41 Market Size (2021-2032)
- 2.2.2 Global Glycoprotein 41 Sales (2021-2032)
- 2.2.3 Global Glycoprotein 41 Market Average Price (2021-2032)
- 2.3 Glycoprotein 41 by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 DS-007
- 2.3.3 LBT-5001
- 2.3.4 LBT-5001
- 2.3.5 MYMV-101
- 2.3.6 Others
- 2.4 Glycoprotein 41 by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Glycoprotein 41 Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Glycoprotein 41 Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Glycoprotein 41 Revenue of Manufacturers (2021-2026)
- 3.4 Global Glycoprotein 41 Average Price by Manufacturers (2021-2026)
- 3.5 Global Glycoprotein 41 Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Glycoprotein 41, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Glycoprotein 41, Product Type & Application
- 3.8 Global Manufacturers of Glycoprotein 41, Established Date
- 3.9 Global Glycoprotein 41 Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Amunix Operating Inc
- 4.1.1 Amunix Operating Inc Company Information
- 4.1.2 Amunix Operating Inc Business Overview
- 4.1.3 Amunix Operating Inc Glycoprotein 41 Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Amunix Operating Inc Glycoprotein 41 Product Portfolio
- 4.1.5 Amunix Operating Inc Recent Developments
- 4.2 Frontier Biotechnologies Inc
- 4.2.1 Frontier Biotechnologies Inc Company Information
- 4.2.2 Frontier Biotechnologies Inc Business Overview
- 4.2.3 Frontier Biotechnologies Inc Glycoprotein 41 Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Frontier Biotechnologies Inc Glycoprotein 41 Product Portfolio
- 4.2.5 Frontier Biotechnologies Inc Recent Developments
- 4.3 InnaVirVax SA
- 4.3.1 InnaVirVax SA Company Information
- 4.3.2 InnaVirVax SA Business Overview
- 4.3.3 InnaVirVax SA Glycoprotein 41 Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 InnaVirVax SA Glycoprotein 41 Product Portfolio
- 4.3.5 InnaVirVax SA Recent Developments
- 4.4 Longevity Biotech Inc
- 4.4.1 Longevity Biotech Inc Company Information
- 4.4.2 Longevity Biotech Inc Business Overview
- 4.4.3 Longevity Biotech Inc Glycoprotein 41 Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Longevity Biotech Inc Glycoprotein 41 Product Portfolio
- 4.4.5 Longevity Biotech Inc Recent Developments
- 4.5 Mymetics Corp
- 4.5.1 Mymetics Corp Company Information
- 4.5.2 Mymetics Corp Business Overview
- 4.5.3 Mymetics Corp Glycoprotein 41 Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Mymetics Corp Glycoprotein 41 Product Portfolio
- 4.5.5 Mymetics Corp Recent Developments
- 4.6 Navigen Inc
- 4.6.1 Navigen Inc Company Information
- 4.6.2 Navigen Inc Business Overview
- 4.6.3 Navigen Inc Glycoprotein 41 Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Navigen Inc Glycoprotein 41 Product Portfolio
- 4.6.5 Navigen Inc Recent Developments
- 4.7 Osel Inc
- 4.7.1 Osel Inc Company Information
- 4.7.2 Osel Inc Business Overview
- 4.7.3 Osel Inc Glycoprotein 41 Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Osel Inc Glycoprotein 41 Product Portfolio
- 4.7.5 Osel Inc Recent Developments
- 4.8 Pharis Biotec GmbH
- 4.8.1 Pharis Biotec GmbH Company Information
- 4.8.2 Pharis Biotec GmbH Business Overview
- 4.8.3 Pharis Biotec GmbH Glycoprotein 41 Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Pharis Biotec GmbH Glycoprotein 41 Product Portfolio
- 4.8.5 Pharis Biotec GmbH Recent Developments
5 Global Glycoprotein 41 Market Scenario by Region
- 5.1 Global Glycoprotein 41 Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Glycoprotein 41 Sales by Region: 2021-2032
- 5.2.1 Global Glycoprotein 41 Sales by Region: 2021-2026
- 5.2.2 Global Glycoprotein 41 Sales by Region: 2027-2032
- 5.3 Global Glycoprotein 41 Revenue by Region: 2021-2032
- 5.3.1 Global Glycoprotein 41 Revenue by Region: 2021-2026
- 5.3.2 Global Glycoprotein 41 Revenue by Region: 2027-2032
- 5.4 North America Glycoprotein 41 Market Facts & Figures by Country
- 5.4.1 North America Glycoprotein 41 Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Glycoprotein 41 Sales by Country (2021-2032)
- 5.4.3 North America Glycoprotein 41 Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Glycoprotein 41 Market Facts & Figures by Country
- 5.5.1 Europe Glycoprotein 41 Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Glycoprotein 41 Sales by Country (2021-2032)
- 5.5.3 Europe Glycoprotein 41 Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Glycoprotein 41 Market Facts & Figures by Country
- 5.6.1 Asia Pacific Glycoprotein 41 Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Glycoprotein 41 Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Glycoprotein 41 Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Glycoprotein 41 Market Facts & Figures by Country
- 5.7.1 South America Glycoprotein 41 Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Glycoprotein 41 Sales by Country (2021-2032)
- 5.7.3 South America Glycoprotein 41 Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Glycoprotein 41 Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Glycoprotein 41 Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Glycoprotein 41 Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Glycoprotein 41 Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Glycoprotein 41 Sales by Type (2021-2032)
- 6.1.1 Global Glycoprotein 41 Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Glycoprotein 41 Sales Market Share by Type (2021-2032)
- 6.2 Global Glycoprotein 41 Revenue by Type (2021-2032)
- 6.2.1 Global Glycoprotein 41 Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Glycoprotein 41 Revenue Market Share by Type (2021-2032)
- 6.3 Global Glycoprotein 41 Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Glycoprotein 41 Sales by Application (2021-2032)
- 7.1.1 Global Glycoprotein 41 Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Glycoprotein 41 Sales Market Share by Application (2021-2032)
- 7.2 Global Glycoprotein 41 Revenue by Application (2021-2032)
- 7.2.1 Global Glycoprotein 41 Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Glycoprotein 41 Revenue Market Share by Application (2021-2032)
- 7.3 Global Glycoprotein 41 Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Glycoprotein 41 Value Chain Analysis
- 8.1.1 Glycoprotein 41 Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Glycoprotein 41 Production Mode & Process
- 8.2 Glycoprotein 41 Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Glycoprotein 41 Distributors
- 8.2.3 Glycoprotein 41 Customers
9 Global Glycoprotein 41 Analyzing Market Dynamics
- 9.1 Glycoprotein 41 Industry Trends
- 9.2 Glycoprotein 41 Industry Drivers
- 9.3 Glycoprotein 41 Industry Opportunities and Challenges
- 9.4 Glycoprotein 41 Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst